Mortimer Poncz

This study identifies PF4 as a central factor in APS by showing it bridges {beta}2GPI to NETs, forming prothrombotic complexes that are targeted by APS antibodies.

This study identifies PF4 as a key regulator of HSC aging, showing that PF4 deficiency accelerates aging and that PF4 supplementation can rejuvenate aged HSCs.

This study identifies platelet factor 4 (PF4) as a mediator of endothelial antimicrobial activity, enhancing bacterial clearance and improving sepsis outcomes through clathrin-mediated endocytosis and reduced immunothrombosis.

This paper shows that m-tirofiban, a non-partial agonist of IIbβ3, effectively inhibits venous thrombosis without increasing bleeding in a mouse model.

The paper shows that lung marginated neutrophils effectively uptake endothelial-targeted nanoparticles, suggesting they are part of the reticuloendothelial system.

This study shows PAI-1 deficiency in PASMC promotes pulmonary vascular remodeling and hypertension by enhancing uPA activity, leading to cell proliferation and reduced apoptosis.

The paper shows that megakaryocytes are entrapped in the lungs, release cytoplasmic fragments, and undergo platelet formation, supporting a pulmonary-centric 'catch-and-release' model of thrombopoiesis.

This study introduces CAPRIs, bispecific antibodies that inhibit platelet activation by clustering G6B with ITAM receptors, showing effectiveness in preventing thrombus formation without causing bleeding.

The paper demonstrates that in vitro-grown megakaryocytes can store exogenous uPA in alpha-granules, which can be used to generate anti-thrombotic human platelets that lyse nascent thrombi in a mouse model.

This study shows that RUNX1 haploinsufficiency reduces megakaryocyte-biased hematopoietic progenitor cells and identifies drug targets to correct this defect.

This study shows that stabilizing neutrophil extracellular traps (NETs) with PF4 and KKO improves outcomes in sepsis by reducing NET degradation products and enhancing bacterial capture.

This study designs a novel orthosteric inhibitor of integrin αIIbβ3 that prevents thrombosis without impairing hemostasis, using structure-guided methods.